<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02222844</url>
  </required_header>
  <id_info>
    <org_study_id>DOCUMAS: 23HH8201</org_study_id>
    <nct_id>NCT02222844</nct_id>
  </id_info>
  <brief_title>Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers</brief_title>
  <acronym>IMPRESS</acronym>
  <official_title>Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pelican Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative&#xD;
      treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical&#xD;
      treatment are eligible. Patient are randomised to the control arm which the standard care of&#xD;
      preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the&#xD;
      interventional arm which has the additional use of MRI imaging and subsequent discussion by&#xD;
      the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL&#xD;
      questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised phase II multicentre trial, IMPRESS will determine whether the use of MRI&#xD;
      imaging in staging sigmoid cancers results in a change to the treatment plan by identifying&#xD;
      more high risk tumours compared to those patients who were staged using CT imaging. The&#xD;
      proposed intervention will be additional radiological and pathological assessment and the&#xD;
      reporting of supplementary diagnostic information which would not otherwise have been&#xD;
      available. This may affect treatment according to local MDT protocols and also affect the&#xD;
      provision of prognostic information to patients in subsequent discussions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observational Phase: To measure the difference in staging of sigmoid cancer on CT and MRI.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Direct comparison of proportion of patients staged as high and low risk for recurrence between CT vs MRI findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Direct comparison of proportion of patients undergoing preoperative treatment or extended surgery between patients staged with CT vs MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the recurrence rates of sigmoid tumours staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Comparison of proportion of recurrences in patients staged as low vs high risk on CT vs MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare disease free survival of patients staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>1 and 3 years after last recruit</time_frame>
    <description>Kaplan-Meier curves of disease free survival in patients staged as low vs high risk on CT vs MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the quality of surgery by pathology of patients staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>5 years</time_frame>
    <description>Grade of specimen using pathology TNM8 stratified by TNM8 staging on CT vs MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare CRM positivity rates on pathology of patients staged by CT and MRI according to predicted prognostic risk</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>CRM positivity rates on pathology in patients staged as low vs high risk on CT vs MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare baseline and post-treatment stage on imaging against pathology and clinical outcomes of patients staged by CT and MRI.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Comparison of proportion of patients staged as low vs high risk on CT vs MRI with pathology high and low risk and against outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare perioperative morbidity and mortality of patients staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Comparison of perioperative morbidity of patients stratified by preoperative treatment between patients staged with CT vs MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life of patients staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>1 and 3 years after last recruit</time_frame>
    <description>Comparison of quality of life between patients staged with CT vs MRI by questionnaire (EORTC QLQ-CR29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.</measure>
    <time_frame>3 years after last recruit</time_frame>
    <description>Comparison of proportion of stomas not reversed within 3 years postoperative follow-up in patients staged with CT vs MRI</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colon, Sigmoid</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>General Surgery</condition>
  <arm_group>
    <arm_group_label>Preoperative CT scan</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative MRI scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment plus an additional MRI scan before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational only</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative MRI scan</intervention_name>
    <description>Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.</description>
    <arm_group_label>Preoperative MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a suspected or proven sigmoid colon adenocarcinoma&#xD;
&#xD;
          2. Is eligible for curative treatment&#xD;
&#xD;
          3. Has no irresectable metastatic disease&#xD;
&#xD;
          4. MRI can be reviewed by an MDT prior to surgery&#xD;
&#xD;
          5. Has no decision regarding radical treatment&#xD;
&#xD;
          6. Have provided written informed consent to participate in the study&#xD;
&#xD;
          7. Be aged 16 years or over&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have metastatic disease (including resectable liver metastases)&#xD;
&#xD;
          2. Have a synchronous second malignancy&#xD;
&#xD;
          3. Are contraindicated for MRI&#xD;
&#xD;
          4. Are contraindicated for or have allergy to Buscopan (e.g. glaucoma, small or large&#xD;
             bowel obstruction, GFR&lt;30)&#xD;
&#xD;
          5. Have severe co-morbidities or previous medical history that prevent the application of&#xD;
             eventual chemo/radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Martin</last_name>
    <phone>+44 (0) 7749 655 817</phone>
    <email>c.martin1@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Syvella Ellis</last_name>
    <phone>+44 (0) 7732 315 234</phone>
    <email>giclinicaltrials@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <state>Cambridgeshire</state>
        <zip>PE29 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mitchell</last_name>
      <email>davidmitchell4@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Susan Donnelly</last_name>
      <email>susan.donnelly1@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>David Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leighton Hospital</name>
      <address>
        <city>Crewe</city>
        <state>Cheshire</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hough</last_name>
      <email>Chris.Hough@mcht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Adamson</last_name>
      <email>Vanessa.Adamson@mcht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Braun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <state>County Durham</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Wilson</last_name>
      <email>Helen.Wilson2@nth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anil Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Croydon University Hospital</name>
      <address>
        <city>Thornton Heath</city>
        <state>Croydon</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muti Abulafi</last_name>
      <email>muti.abulafi@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Ibiyemi Sadare</last_name>
      <email>ibiyemi.sadare@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Muti Abulafi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesterfield Royal</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>SS4 5BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Stevenson</last_name>
      <email>lesley.stevenson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Harjeet Singh Narula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Higginson</last_name>
      <email>antony.higginson@porthosp.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Gibbons</last_name>
      <email>nicola.gibbons@porthosp.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Higginson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Middlesex</city>
        <state>Harrow</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Antoniou</last_name>
      <email>a.antoniou1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Pooja Datt</last_name>
      <email>pooja.datt@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Antoniou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Basham</last_name>
      <email>paulette.basham@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sukanya Ghosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth the Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <state>Kent</state>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Turney</last_name>
      <email>sharon.turney@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jess Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Crumpsall</city>
        <state>Manchester</state>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salim Kurrimboccus</last_name>
      <email>Salim.Kurrimboccus@pat.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Allsop</last_name>
      <email>Joanne.Allsop@pat.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Salim Kurrimbossus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester &amp; Manchester Royal Infirmary</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Duff</last_name>
      <email>Sarah.Duff@UHSM.NHS.UK</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Piper</last_name>
      <email>Lindsay.Piper@UHSM.NHS.UK</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Duff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>North Yorkshire</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Leinhardt</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Jones</last_name>
      <email>Lisa.Jones@hdft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Leinhardt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Ashcroft</last_name>
      <email>Jan.ashcroft@tst.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Erica Beaumont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cordelia Grant</last_name>
      <email>cordelia.grant@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Irene Chong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>Whiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Branagan</last_name>
      <email>Graham.Branagan@salisbury.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Casey</last_name>
      <email>Ruth.Casey@salisbury.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Graham Branagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>August 29, 2023</last_update_submitted>
  <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colon, Sigmoid</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>General Surgery</keyword>
  <keyword>Postoperative Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Sigmoid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02222844
org study id: DOCUMAS: 23HH8201
nct id: NCT02222844
lead sponsor: 
collaborator: 
has dmc: Yes
Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative
      treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical
      treatment are eligible. Patient are randomised to the control arm which the standard care of
      preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the
      interventional arm which has the additional use of MRI imaging and subsequent discussion by
      the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL
      questionnaires.
A randomised phase II multicentre trial, IMPRESS will determine whether the use of MRI
      imaging in staging sigmoid cancers results in a change to the treatment plan by identifying
      more high risk tumours compared to those patients who were staged using CT imaging. The
      proposed intervention will be additional radiological and pathological assessment and the
      reporting of supplementary diagnostic information which would not otherwise have been
      available. This may affect treatment according to local MDT protocols and also affect the
      provision of prognostic information to patients in subsequent discussions.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Diagnostic
masking: None (Open Label)
measure: Observational Phase: To measure the difference in staging of sigmoid cancer on CT and MRI.
time frame: 3 years after last recruit
description: Direct comparison of proportion of patients staged as high and low risk for recurrence between CT vs MRI findings
measure: Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.
time frame: 3 years after last recruit
description: Direct comparison of proportion of patients undergoing preoperative treatment or extended surgery between patients staged with CT vs MRI
measure: To compare the recurrence rates of sigmoid tumours staged by CT and MRI according to predicted prognostic risk.
time frame: 3 years after last recruit
description: Comparison of proportion of recurrences in patients staged as low vs high risk on CT vs MRI
measure: To compare disease free survival of patients staged by CT and MRI according to predicted prognostic risk.
time frame: 1 and 3 years after last recruit
description: Kaplan-Meier curves of disease free survival in patients staged as low vs high risk on CT vs MRI
measure: To compare the quality of surgery by pathology of patients staged by CT and MRI according to predicted prognostic risk.
time frame: 5 years
description: Grade of specimen using pathology TNM8 stratified by TNM8 staging on CT vs MRI
measure: To compare CRM positivity rates on pathology of patients staged by CT and MRI according to predicted prognostic risk
time frame: 3 years after last recruit
description: CRM positivity rates on pathology in patients staged as low vs high risk on CT vs MRI
measure: To compare baseline and post-treatment stage on imaging against pathology and clinical outcomes of patients staged by CT and MRI.
time frame: 3 years after last recruit
description: Comparison of proportion of patients staged as low vs high risk on CT vs MRI with pathology high and low risk and against outcomes
measure: To compare perioperative morbidity and mortality of patients staged by CT and MRI according to predicted prognostic risk.
time frame: 3 years after last recruit
description: Comparison of perioperative morbidity of patients stratified by preoperative treatment between patients staged with CT vs MRI
measure: To compare quality of life of patients staged by CT and MRI according to predicted prognostic risk.
time frame: 1 and 3 years after last recruit
description: Comparison of quality of life between patients staged with CT vs MRI by questionnaire (EORTC QLQ-CR29)
measure: To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.
time frame: 3 years after last recruit
description: Comparison of proportion of stomas not reversed within 3 years postoperative follow-up in patients staged with CT vs MRI
arm group label: Preoperative CT scan
arm group type: No Intervention
description: CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
arm group label: Preoperative MRI scan
arm group type: Experimental
description: Standard treatment plus an additional MRI scan before surgery
arm group label: Observational
arm group type: No Intervention
description: Observational only
intervention type: Other
intervention name: Preoperative MRI scan
description: Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
arm group label: Preoperative MRI scan
criteria: 
gender: All
minimum age: 16 Years
maximum age: N/A
healthy volunteers: No
last name: Gina Brown
role: Principal Investigator
affiliation: Imperial College London
last name: Caroline Martin
phone: +44 (0) 7749 655 817
email: c.martin1@imperial.ac.uk
last name: Syvella Ellis
phone: +44 (0) 7732 315 234
email: giclinicaltrials@imperial.ac.uk
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Active, not recruiting
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Colorectal Neoplasms
mesh term: Sigmoid Neoplasms